After nearly a decade in development, a device to treat breast cancer that was developed at the University of Maryland School of Medicine has a key clearance toward going to market.
The U.S. Food and Drug Administration gave a 510(k) medical device clearance to the GammaPod, a device which treats early-stage breast cancer. The announcement was made in December.
“During radiation therapy, tumor cells are killed when their DNA is damaged by the radiation being absorbed into them. While radiation therapy has the potential to kill tumor cells, it can also damage healthy tissue around the tumor,” the FDA stated.
READ FULL ARTICLE HERE
